Fig. 2. Prognostic impact of Orai3 and STIM2 expression in renal cell carcinoma (RCC) subtypes.
(A, C) FPKM for Orai3 according to normal and RCC grades (Stage I, II, III, and IV) in clear cell RCC (ccRCC) and papillary RCC (pRCC), respectively. Box whisker plots express the minimum, median, and maximum values of FPKM (expressed as log(expr + 1)), where FPKM was adjusted using a scaling factor instead of total mapped reads to remove a million units. ***p ≤ 0.001 of one-way ANOVA (normal vs. tumor stages). (B, D) Kaplan–Meler survival analysis comparing females (left) and males (right) in the low and high mRNA levels of Orai3 in ccRCC and pRCC, respectively. The cut-off value for Orai3 in ccRCC is 13.5, and in pRCC is 16.87. (E, G) Correlation analysis between gene copy number (log2-transformed values) of STIM2 and Orai3 in ccRCC (total n = 355) and pRCC (total n = 241), respectively. The linear regression line with a 95% confidence interval and the Spearman r correlation coefficient. (F, H) Kaplan–Meler survival analysis comparing males and females with high Orai3 and low STIM2 mRNA levels in ccRCC and pRCC, respectively. The cut-off value for Orai3 is 13, and for STIM2 is 4.5. p-values were determined by a log-rank test (B, D, F, and H).
© Korean J Physiol Pharmacol
